Cohort Profile Update: The Swiss HIV Cohort Study (SHCS)

Scherrer, Alexandra U.; Traytel, Anna; Braun, Dominique L; Calmy, Alexandra; Battegay, Manuel; Cavassini, Matthias; Furrer, Hansjakob; Schmid, Patrick; Bernasconi, Enos; Stoeckle, Marcel; Kahlert, Christian; Trkola, Alexandra; Kouyos, Roger D.; Tarr, Philip E.; Marzolini, Catia; Wandeler, Gilles; Fellay, Jacques; Bucher, Heiner C.; Yerly, Sabine; Suter, F.; Hirsch, Hans H.; Huber, Michael; Dollenmaier, Günter; Perreau, Matthieu; Martinetti, Gladys; Rauch, Andri; Günthard, Huldrych F.

doi:10.1093/ije/dyab141

Cited by 100 publications

(75 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…By examining previously published data ( 23 ), we found that three other individuals from the SHCS were closely related (a phylogenetic distance below 2.5%). The high coverage of the Swiss HIV Cohort [including 89% of reported new infections from 2009 through 2018, with ~65% of the cohort sequenced ( 24 )] makes it unlikely that many more VB individuals in Switzerland were undetected. Data to assess viral load or CD4 cell decline for these three individuals were not available, owing to early initiation of treatment.…”

Section: Search For Closely Related Virusesmentioning

confidence: 99%

A highly virulent variant of HIV-1 circulating in the Netherlands

Wymant

Bezemer

Blanquart

et al. 2022

Science

Self Cite

View full text Add to dashboard Cite

We discovered a highly virulent variant of subtype-B HIV-1 in the Netherlands. One hundred nine individuals with this variant had a 0.54 to 0.74 log 10 increase (i.e., a ~3.5-fold to 5.5-fold increase) in viral load compared with, and exhibited CD4 cell decline twice as fast as, 6604 individuals with other subtype-B strains. Without treatment, advanced HIV—CD4 cell counts below 350 cells per cubic millimeter, with long-term clinical consequences—is expected to be reached, on average, 9 months after diagnosis for individuals in their thirties with this variant. Age, sex, suspected mode of transmission, and place of birth for the aforementioned 109 individuals were typical for HIV-positive people in the Netherlands, which suggests that the increased virulence is attributable to the viral strain. Genetic sequence analysis suggests that this variant arose in the 1990s from de novo mutation, not recombination, with increased transmissibility and an unfamiliar molecular mechanism of virulence.

show abstract

Section: Search For Closely Related Virusesmentioning

confidence: 99%

A highly virulent variant of HIV-1 circulating in the Netherlands

Wymant

Bezemer

Blanquart

et al. 2022

Science

Self Cite

View full text Add to dashboard Cite

show abstract

“…The Swiss HIV Cohort Study (SHCS) is a prospective multicenter cohort study enrolling adult people living with HIV in Switzerland [ 15 , 17 ]. The study was launched in 1988, is approved by all local research ethics committees.…”

Section: Methodsmentioning

confidence: 99%

“…With its modular design, one can implement independent tools and features within the productive environment and make them visible to specific subsets of users. The SHCS covers around 75% of all individuals on antiretroviral therapy in Switzerland and is representative of the HIV epidemic in this country [ 15 , 17 ].…”

Section: Methodsmentioning

confidence: 99%

“…In this project, we aimed to develop a trial platform within the framework of the Swiss HIV Cohort Study (SHCS) and Swiss Transplant Cohort Study (STCS), two well-established nation-wide cohort studies [ 15 , 16 ]. We aimed to develop an interoperable system embedded in the data collection of two running cohort studies ensuring transfer of baseline data.…”

Section: Background and Purposementioning

confidence: 99%

See 1 more Smart Citation

Developing and testing a Corona VaccinE tRiAL pLatform (COVERALL) to study Covid-19 vaccine response in immunocompromised patients

Kusejko

Chammartin²,

Smith³

et al. 2022

BMC Infect Dis

Self Cite

View full text Add to dashboard Cite

Background The rapid course of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic calls for fast implementation of clinical trials to assess the effects of new treatment and prophylactic interventions. Building trial platforms embedded in existing data infrastructures is an ideal way to address such questions within well-defined subpopulations. Methods We developed a trial platform building on the infrastructure of two established national cohort studies: the Swiss human immunodeficiency virus (HIV) Cohort Study (SHCS) and Swiss Transplant Cohort Study (STCS). In a pilot trial, termed Corona VaccinE tRiAL pLatform (COVERALL), we assessed the vaccine efficacy of the first two licensed SARS-CoV-2 vaccines in Switzerland and the functionality of the trial platform. Results Using Research Electronic Data Capture (REDCap), we developed a trial platform integrating the infrastructure of the SHCS and STCS. An algorithm identifying eligible patients, as well as baseline data transfer ensured a fast inclusion procedure for eligible patients. We implemented convenient re-directions between the different data entry systems to ensure intuitive data entry for the participating study personnel. The trial platform, including a randomization algorithm ensuring balance among different subgroups, was continuously adapted to changing guidelines concerning vaccination policies. We were able to randomize and vaccinate the first trial participant the same day we received ethics approval. Time to enroll and randomize our target sample size of 380 patients was 22 days. Conclusion Taking the best of each system, we were able to flag eligible patients, transfer patient information automatically, randomize and enroll the patients in an easy workflow, decreasing the administrative burden usually associated with a trial of this size.

show abstract

“…With the continuous raising efficacy of antiretroviral therapies (ART) combinations, the characteristics of the HIV population are changing. Life expectancy of people living with HIV (PLWH) is now close to that of the HIV-uninfected population, resulting in PLWH being an aging population, with an increasing proportion of patients over the age of 50, reaching more than 50% in European countries or in the USA [ 1 , 2 ].Therefore, PLWH are at greater risk of developing age-related non-communicable diseases, including osteoporosis and fractures, and more attention is needed to prevent or treat these comorbidities [ 3 , 4 ]. Meanwhile, the majority of PLWH now have an undetectable viral load with stable ART.…”

Section: Introductionmentioning

confidence: 99%

Osteoporosis and HIV Infection

Biver

2022

Calcif Tissue Int

View full text Add to dashboard Cite

Life expectancy of people living with HIV (PLWH) is now close to that of the HIV-uninfected population. As a result, age-related comorbidities, including osteoporosis, are increasing in PLWH. This narrative review describes the epidemiology of bone fragility in PLWH, changes of bone features over the course of HIV infection and their determinants, as well as the available evidence regarding the management of osteoporosis in PLWH. The risk of fracture is higher and increases about 10 years earlier compared to the general population. The classical risk factors of bone fragility are very widespread and are major determinants of bone health in this population. The majority of bone loss occurs during virus replication and during immune reconstitution at antiretroviral therapies (ART) initiation, which both increase osteoclast activity. Abnormalities in bone formation and mineralization have also been shown in histomorphometric studies in untreated PLWH. Measurement of bone mineral density (BMD) is the first line tool for assessing fracture risk in postmenopausal women, men above 50 years, and other HIV-infected patients with clinical risk factors for osteoporosis. FRAX underestimates fracture probability in PLWH. In case of indication for anti-osteoporotic drug, bisphosphonates remain the reference option. Calcium and vitamin D supplementation should be considered as ART initiation, since it may attenuate bone loss at this stage. Bone-protective ART regimens improve BMD compared to other regimens, but to a lesser extent than bisphosphonate, and without available data on their influence on the incidence of fracture.

show abstract

Cohort Profile Update: The Swiss HIV Cohort Study (SHCS)

Cited by 100 publications

References 60 publications

A highly virulent variant of HIV-1 circulating in the Netherlands

A highly virulent variant of HIV-1 circulating in the Netherlands

Developing and testing a Corona VaccinE tRiAL pLatform (COVERALL) to study Covid-19 vaccine response in immunocompromised patients

Osteoporosis and HIV Infection

Contact Info

Product

Resources

About